Vogliviga M 0.3 Tablet is a bilayered smart combination formulation that unites two essential antidiabetic agents: Metformin (500mg) in a sustained release (SR) form and Voglibose (0.3mg). This dual-action tablet is specifically designed for effective glycemic management in adult patients with type 2 diabetes mellitus who are not adequately controlled by diet, exercise, or monotherapy.
Metformin is a biguanide that helps lower blood glucose levels by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. Its sustained-release property allows for prolonged drug action and minimized gastrointestinal disturbances, offering better patient compliance and tolerability.
Voglibose, an alpha-glucosidase inhibitor, works by delaying the digestion and absorption of carbohydrates in the small intestine. This slows down the rise in postprandial blood glucose levels and reduces glucose fluctuations after meals, an essential factor in maintaining tight glycemic control and preventing complications.
The bilayered smart tablet design allows for a controlled release of Metformin and immediate release of Voglibose. This ensures efficient action at different stages of glucose absorption and metabolism, providing a well-rounded, time-optimized therapeutic effect.
Vogliviga M 0.3 is ideal for patients requiring dual therapy with both basal glucose control and postprandial regulation. This combination helps in reducing insulin resistance, managing spikes in glucose levels after meals, and lowering overall HbA1c levels.
Regular use of this formulation, along with a balanced diabetic-friendly diet and physical activity, aids in the long-term management of type 2 diabetes, potentially preventing complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease.
This tablet offers the convenience of a single dosage form with the advantage of multiple mechanisms of action, thereby simplifying treatment regimens for better adherence and improved clinical outcomes.